TITLE:
Insulin, Neurogenetics and Memory in Alzheimer's Disease

CONDITION:
Alzheimer Disease

INTERVENTION:
rosiglitazone

SUMMARY:

      This study examines the use of insulin-sensitizing compounds, as therapeutic agents for
      cognitive impairment in Alzheimer's disease.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 55 Years to 80 Years
Criteria:

        Men and women with mild Alzheimer's Disease without serious medical or psychiatric
        comorbid conditions.
      
